• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Evelo Biosciences Inc.

    1/26/24 5:30:25 PM ET
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVLO alert in real time by email
    15-12G 1 d703847d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38473

     

     

    EVELO BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

    124 Washington Street, Suite 101

    Foxborough, Massachusetts 02035

    (508) 543-1720

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      

    ☒

    Rule 12g-4(a)(2)

      

    ☐

    Rule 12h-3(b)(1)(i)

      

    ☐

    Rule 12h-3(b)(1)(ii)

      

    ☐

    Rule 15d-6

      

    ☒

    Rule 15d-22(b)

      

    ☐

    Approximate number of holders of record as of the certification or notice date: 36

    Pursuant to the requirements of the Securities Exchange Act of 1934 Evelo Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        EVELO BIOSCIENCES, INC.
    Date: January 26, 2024     By:  

    /s/ Craig R. Jalbert

          Craig R. Jalbert
          Chief Executive Officer, President, Director

     

     

     

    Get the next $EVLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVLO

    DatePrice TargetRatingAnalyst
    11/2/2021$44.00 → $41.50Market Outperform
    JMP Securities
    11/1/2021$12.00Neutral → Buy
    Chardan Capital Markets
    6/23/2021$36.00 → $38.00Market Outperform
    JMP Securities
    6/23/2021$28.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bodmer Mark converted options into 6,625 shares and sold $1,044 worth of shares (3,163 units at $0.33), increasing direct ownership by 16% to 25,732 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:53 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mchale Duncan converted options into 6,500 shares and sold $1,024 worth of shares (3,103 units at $0.33), increasing direct ownership by 25% to 16,984 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:32:28 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gill Simba sold $57 worth of shares (172 units at $0.33) and converted options into 1,172 shares, increasing direct ownership by 6% to 17,758 units (SEC Form 4)

      4 - Evelo Biosciences, Inc. (0001694665) (Issuer)

      11/8/23 8:31:56 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously

      11/2/21 7:54:09 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00

      11/1/21 8:36:16 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously

      6/23/21 1:58:41 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care